COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck(R/M SCCHN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03855384
Recruitment Status : Recruiting
First Posted : February 26, 2019
Last Update Posted : October 30, 2019
Information provided by (Responsible Party):
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary:
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Head and Neck Drug: TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU) Drug: placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 334 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN)
Actual Study Start Date : June 11, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : May 30, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU) Drug: TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
TQB2450 1200mg IV ,cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).

Placebo Comparator: placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU) Drug: placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
placebo 1200mg IV ,cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).

Primary Outcome Measures :
  1. OS [ Time Frame: up to 72 weeks ]
    Overall survival

Secondary Outcome Measures :
  1. DOR [ Time Frame: up to 72 weeks ]
    Duration of Response

  2. PFS [ Time Frame: up to 24 weeks ]
    Progression-free survival

  3. DCR [ Time Frame: up to 24 weeks ]
    Disease Control Rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologically confirmed head and neck squamous cell carcinoma ,primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx.
  2. No indications of local radical therapy for recurrence/metastasis head and neck squamous cell carcinoma.
  3. At least one measurable lesion( based on RECIST1.1).
  4. Can provide tissue for PD-L1 biomarker analysis: A newly obtained biopsy is preferred but an archival sample is acceptable.
  5. Tumors express PD-L1,and PD-L1 expression on at least 1% of tumour cells .
  6. 18 years and older.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  8. Life expectancy of at least 3 months.
  9. The main organs function are normally, the following criteria are met:

    1. routine blood tests:hemoglobin(Hb)≥90g/L(no blood transfusion and blood products within 14 days);absolute neutrophil count(ANC)≥1.5×109/L; platelets(PLT)≥100×109/L.
    2. Blood biochemical examination: alanine transaminase(ALT)and aspartate aminotransferase(AST)≤2.5×upper limit of normal (ULN)(when the liver is invaded, ALT, and AST ≤5× upper limit of normal (ULN) ); total bilirubin (TBIL)≤1.5×upper limit of normal (ULN)(Gilbert syndrome patients,≤3×upper limit of normal (ULN)); calculated creatinine clearance(CrCl)≥60mL/min(Creatinine clearance criteria for subjects treated with cisplatin)or CrCl≥50mL/min(Creatinine clearance criteria for subjects treated with carboplatin)(Application of Standard Cockcroft-Gault Formula).
    3. Coagulation function: activated partial thromboplastin time (aPTT) 、 international normalized ratio (INR) 、prothrombin time(PT)≤ 1.5×upper limit of normal (ULN).
    4. left ventricular ejection fraction (LVEF) measured by the Cardiac echocardiography greater than or equal to 50%.
  10. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study(Such as intrauterine devices , birth control pills or condoms) ;Not Pregnant or breastfeeding women,Pregnancy before pregnancy screening(Within 7 days before the start of the study), the women who blood / urine results were positive.
  11. Understood and signed an informed consent form.

Exclusion Criteria:

  1. Received systemic chemotherapy, but not chemotherapy for locally advanced disease as part of multimodality therapy (this treatment must be completed more than 6 months after informed consent).
  2. Has progressive disease (PD) within six (6) months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
  3. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody ,or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  4. Patients who have received cetuximab treatment within 6 moths before randomization.
  5. Diagnosed and/or treated additional malignancy within 5 years prior to randomization with the exception of cured carcinoma in situ of the cervix、intramucosal carcinoma of gastrointestinal tract、breast and non-melanoma skin cancers and superficial bladder tumors.
  6. Known untreated central nervous system (CNS) metastasis and/or carcinomatous meningitis. 7. Has neuropathy that is ≥ Grade 2 by Common Terminology Criteria for Adverse Events (CTCAE) version 5 criteria.

8. Previously had a severe hypersensitivity reaction to treatment with study drug or has a known sensitivity to any component of drug , including Severe hypersensitivity reaction≥3 grades (NCI CTCAEv5.0 )to monoclonal antibody 、fluorouracil、 carboplatin or cisplatin-related compounds.

9. Active autoimmune disease that may worsen with the administration of an immunostimulant. Patients with type 1 diabetes, vitiligo, psoriasis, or hypothyroidism or hyperthyroidism that do not require immunosuppression therapy are excluded.

10. Immunosuppressive drugs were used at randomization,except that:

  1. Intranasal, inhaled, topical steroid or topical steroid injection (e.g. intra-articular injection)
  2. Physiological doses of systemic corticosteroids (a dose of ≤ 10 mg daily prednisone (or equivalent) )
  3. Preadministration of steroids for hypersensitivity reactions (e.g., preadministration of CT scans)" 11. Interstitial lung disease or non-contagious pneumonia (including past history and current illness); uncontrolled systemic diseases including diabetes, hypertension,acute lung disease, etc. except for radiotherapy-induced interstitial pneumonitis.

    12. Has any other active infection requiring systemic therapy,including patients with active tuberculosis.

    13. Unstable pleural effusion, pericardial effusion or ascites. 14. Significant cardiovascular diseases such as heart failure of New York Heart Academy(NYHA) Class 2 and above, myocardial infarction within the past 3 months, unstable arrhythmias (including QT interval ≥480 ms) or unstable Angina.

    15. Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history.

    16. Virological examination of hepatitis B or hepatitis C during screening meets any of the following criteria:

a. HBsAg positive and HBV DNA positive (≥1000 copies /mL); b. HCV antibody and HCV-RNA positive(The result is greater than the detection limit of the analytical method).

17. Major surgery, or unhealed wounds, ulcers or fractures within 4 weeks before randomization.

18.Has received a live-virus vaccination within 4 weeks before randomization ,allowing received seasonal flu vaccines without live viruses.

19. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.

20. Investigator judges that the patient is not eligible to join the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03855384

Layout table for location contacts
Contact: Ye Guo, doctor 021-38804518

Layout table for location information
China, Shanghai
Shanghai East Hospital Recruiting
Shanghai, Shanghai, China
Contact: Ye Guo, Doctor    021-38804518   
Principal Investigator: Ye Guo         
Sponsors and Collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Layout table for additonal information
Responsible Party: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Identifier: NCT03855384    
Other Study ID Numbers: TQB2450-II-03
First Posted: February 26, 2019    Key Record Dates
Last Update Posted: October 30, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs